Continuous Renal Replacement Therapy Market

The continuous renal replacement therapy market is expected to expand from US$ 1.67 billion in 2024 to US$ 2.98 billion by 2031. The market is projected to achieve a CAGR of 8.7% from 2025 to 2031.

Market Insights and Analyst View:

This report outlines growth opportunities based on the current trends in the continuous renal replacement therapy market and their anticipated effects during the forecast period.

Continuous renal replacement therapy (CRRT) is a critical treatment for patients experiencing severe acute kidney injury (AKI), fluid overload, and uremia, which can lead to life-threatening metabolic disturbances. The rising demand for pediatric CRRT devices and the high incidence of chronic diseases that result in kidney disorders are driving the growth of the continuous renal replacement therapy market. However, the significant risk of major adverse kidney events (MAKE) poses a challenge to market expansion.

Market Drivers:

High Prevalence of Chronic Diseases Leading to Kidney Disorders

Globally, 1 in 10 individuals is affected by chronic kidney disease (CKD), a prevalent and potentially fatal condition. Between 2015 and 2019, diabetes and hypertension were responsible for 75% of kidney failure cases. According to the National Kidney Foundation's 2020 estimates, approximately 30% of the diabetic population over 20 years old in the US is at risk of developing CKD during their lifetime. Furthermore, CKD caused more fatalities than prostate or breast cancer in 2020, highlighting its status as an under-recognized health emergency. About 1 in 3 American adults (around 80 million people) are at risk of CKD, which is now recognized as a significant risk factor for AKI. A decreased glomerular filtration rate (GFR) and increased proteinuria are closely linked to AKI.

The National Institute of Health reports a rising incidence of AKI in developed nations, with its prevalence among hospitalized patients expected to reach 15%, and even higher in critically ill patients at 60%. The global incidence of AKI in hospitalized patients ranges from 0.7% to 31%, with ICU patients experiencing rates exceeding 50%. Between 3% and 13% of AKI patients require renal replacement therapy (RRT), and 40% of these patients are estimated to need CRRT for over 90 days. Thus, the high prevalence of chronic diseases leading to kidney disorders significantly enhances the growth of the continuous renal replacement therapy market.

However, CRRT is associated with adverse effects such as hypotension, tachycardia, and other arrhythmias, which can negatively impact patient conditions or hinder recovery. Additionally, the CRRT circuit may lead to the rapid clearance of micronutrients, trace elements, and/or therapeutic drugs, resulting in low or inconsistent concentrations in blood and tissues, which can cause adverse effects or diminish therapeutic efficacy. Consequently, these adverse effects limit the growth of the continuous renal replacement therapy market.

Strategic Insights

Report Segmentation and Scope:

The analysis of the continuous renal replacement therapy market has been conducted by examining the following segments: product, modality, and end user.

Segmental Analysis:

The continuous renal replacement therapy market is categorized by product into dialysates and replacement fluids, disposables, bloodline sets and tubes, CRRT systems, and hemofilters. The CRRT systems segment held the largest market share in 2022, while the hemofilters segment is expected to exhibit the highest CAGR from 2022 to 2030.

By modality, the continuous renal replacement therapy market is divided into continuous venovenous hemofiltration (CVVH), continuous venovenous hemodiafiltration (CVVHDF), continuous venovenous hemodialysis (CVVHD), and slow continuous ultrafiltration (SCUF). The CVVH segment accounted for the largest market share in 2022, with the CVVHDF segment anticipated to achieve the highest CAGR during 2022-2030.

By end user, the continuous renal replacement therapy market is segmented into hospitals, ambulatory care centers, home care, and others. In 2022, the hospitals segment dominated the market share, but the home monitoring segment is projected to register the highest CAGR from 2022 to 2030.

Regional Analysis:

The continuous renal replacement therapy market report covers North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

In terms of revenue, North America led the continuous renal replacement therapy market in 2022. The Asia Pacific market is expected to register the highest CAGR from 2022 to 2030, driven by improvements in healthcare infrastructure and the adoption of innovative CRRT technologies, which are linked to increasing healthcare expenditures. Additionally, strategic initiatives by market players to enhance their presence in the Asia Pacific region, such as partnerships with local healthcare providers, support market growth in this area.

Continuous Renal Replacement Therapy Market Report Scope

Competitive Landscape and Key Companies:

The continuous renal replacement therapy market report focuses on key players such as Baxter International Inc, Asahi Kasei, Fresenius Medical Care, Medica S.p.A., Medtronic Plc, B. Braun, Nikkiso Co Ltd, Toray Medical Co Ltd, Infomed SA, and Quanta Dialysis Technologies Inc. The forecast for the continuous renal replacement therapy market can assist stakeholders in planning their growth strategies. These companies are concentrating on launching new technologies, enhancing existing products, and expanding their operations to meet the increasing global consumer demand.

1. In April 2022, the US Food and Drug Administration (FDA) granted 510(k) clearance for the ST Set by Baxter International Inc. for use in continuous renal replacement therapy (CRRT). The ST Set is a pre-connected, disposable, extracorporeal circuit that facilitates blood purification through a semipermeable membrane, designed for use with the PrisMax or Prismaflex control units (monitors).
2. In March 2022, Nipro Medical Corporation (Nipro), a leading manufacturer and supplier of renal, vascular, and medical-surgical products, announced the commercial launch of the SURDIAL DX Hemodialysis System in the US. The SURDIAL DX is a cutting-edge hemodialysis system aimed at providing an optimal dialysis treatment experience for both patients and clinicians. Manufactured in Japan, this product is based on over 35 years of expertise in renal device innovation from Nipro’s parent company, Nipro Corporation.

This product will be delivered within 3-5 business days.